This recombinant monoclonal antibody is developed as a research-grade biosimilar to daclizumab, targeting IL2RA (interleukin-2 receptor alpha chain, also known as CD25). IL2RA is a critical component of the high-affinity IL-2 receptor complex, expressed primarily on activated T cells, regulatory T cells, and certain immune cell subsets. By binding to IL2RA, this antibody blocks IL-2 signaling, a pathway essential for T cell proliferation, differentiation, and immune response regulation. Dysregulation of IL2RA expression is implicated in various conditions including autoimmune diseases, transplant rejection, and hematological malignancies, making it a valuable therapeutic target for immune modulation.
Daclizumab, the reference antibody, is a humanized IgG1 monoclonal antibody originally developed for preventing acute organ rejection in transplant recipients. This biosimilar provides researchers with a cost-effective tool for investigating IL-2/IL2RA-mediated immune mechanisms, studying T cell biology, exploring immunosuppressive strategies, and evaluating therapeutic approaches for autoimmune disorders and transplantation research. It serves as an important reagent for immunological studies requiring specific IL2RA blockade.
Email: support@cusabio.com
Distributors Worldwide